Last reviewed · How we verify
NCT06739317
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Phase 2, PHASE3 trial testing Radiation in Unresectable Hepatocellular Carcinoma (HCC) in 398 participants. Not yet recruiting.
31 December 2030
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 398 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2030 |
| Estimated completion | 30 June 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- Radiation
- First line therapy — full drug profile →
- First line therapy — full drug profile →
- operation
Conditions studied
- Unresectable Hepatocellular Carcinoma (HCC) — all drugs for Unresectable Hepatocellular Carcinoma (HCC) →
Sponsor
Sun Yat-sen University
Who can join
18 and older, any sex, with Unresectable Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06739317
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiation
Trials testing the same drug.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07141147 — A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Lo · NA · not yet recruiting
- NCT06270888 — Hypofractionation (Radiation) Trial for Multiple Myeloma · Phase 1 · recruiting
- NCT06875583 — The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial · NA · recruiting
- NCT07046221 — Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery · Phase 2 · not yet recruiting
Other recruiting trials for Unresectable Hepatocellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07391839 — MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. · Phase 1 · recruiting
- NCT07408804 — Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib M · NA · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06739317 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06739317.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing